Found 5 results
Author Title [ Type(Desc)] Year
Filters: Author is Scott, Ingrid U  [Clear All Filters]
Journal Article
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., King, J., Antoszyk, A. N., Peters, M. A., and Tolentino, M., Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4, JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., and Berinstein, D. M., Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial, JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., and King, J., Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial, JAMA, 2017.
J. S. Peterson, Rockwell, K., Scott, I. U., Ip, M. S., VanVeldhuisen, P. C., and Blodi, B. A., Long-Term Physical Stability, Sterility, and Anti-VEGF Bioactivity of Repackaged Bevacizumab in 2-ML Glass Vials, Retina, 2018.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion, Am J Ophthalmol, vol. 184, pp. 147-156, 2017.